Ardelyx Inc (NASDAQ:ARDX) Sellers Decreased Their Shorts By 5.41%

May 16, 2018 - By Sonya McDaniel

Ardelyx, Inc. (NASDAQ:ARDX) Corporate Logo

It was registered a decrease on Ardelyx Inc (NASDAQ:ARDX)’s short interest with 5.41%. FINRA issued in May ARDX’s total 1.34M short interest. The 1.41 million previous shares are down with 5.41%. 4 days will cost ARDX with 357,700 average volume to recover its former position. 4.85% is Ardelyx Inc float short.

Ticker’s shares touched $5.75 during the last trading session after 1.77% change.Ardelyx, Inc. has volume of 142,074 shares. Since May 16, 2017 ARDX has declined 60.67% and is downtrending. The stock underperformed the S&P500 by 72.22%.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States.The company has $273.72 million market cap. The Company’s lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis.Last it reported negative earnings. The firm is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications.

Ardelyx, Inc. (NASDAQ:ARDX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.